PulteGroup News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.01.18	Georgia Power and PulteGroup partner for first Smart Neighborhood™ in Atlanta (PR Newswire)
02.01.18	PharmaMar Signs Agreement For Aplidin With Megapharm In Israel (RTTNews)
24.10.17	PulteGroup, Inc. Announces 22% Gain In Q3 Earnings (RTTNews)
20.09.17	PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors (PR Newswire)
20.09.17	PharmaMar débute des études cliniques avec un nouveau composé, PM14, chez des patients atteints de tumeurs solides (PR Newswire)
20.09.17	PharmaMar startet klinische Studien mit einem neuen Präparat -PM14- bei Patienten mit soliden Tumoren (PR Newswire)
20.09.17	PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors (PR Newswire)
14.09.17	Neue positive Daten zeigen Ansprechrate von 36 % auf PM1183-Monotherapie bei Patienten mit fortgeschrittenem oder rückfälligem kleinzelligem Lungenkarzinom (PR Newswire)
12.09.17	Neue positive Daten zeigen Ansprechrate von 36 % auf PM1183-Monotherapie bei Patienten mit fortgeschrittenem oder rückfälligem kleinzelligem Lungenkarzinom (PR Newswire)
12.09.17	New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer (PR Newswire)
12.09.17	De nouvelles donnees positives sur le PM1183 voient un taux de reponse de 36 % quand il est utilise comme simple agent chez des patients atteints de cancer du poumon a petites cellules avance et... (PR Newswire)
12.09.17	New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer (PR Newswire)
01.09.17	PharmaMar stellt auf dem ESMO 2017 neue klinische Daten zu PM1183 vor (PR Newswire)
31.08.17	PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017 (PR Newswire)
31.08.17	PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017 (PR Newswire)
15.08.17	Today's Research Report Coverage on Residential Construction Stocks -- PulteGroup, Taylor Morrison Home, Toll Brothers, and TRI Pointe (PR Newswire)
09.08.17	PharmaMar Starts a Quadruple Combination Study With Aplidin® for the Treatment of Multiple Myeloma (PR Newswire)
01.08.17	Despite Recent Slowdown, Outlook for New Builder Projects Continue to Improve (PR Newswire)
01.08.17	Despite Recent Slowdown, Outlook for New Builder Projects Continue to Improve (PR Newswire)
25.07.17	PulteGroup, Inc. Profit Climbs 17% In Q2 (RTTNews)
06.07.17	Technical Snapshots for These Residential Construction Stocks -- PulteGroup, D.R. Horton, KB Home, and Toll Brothers (PR Newswire)
20.06.17	FDA Chooses Zepsyre™ (PM1183) from PharmaMar to Explore Potential Development for Pediatric Cancers (PR Newswire)
16.06.17	PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre™ (PR Newswire)
13.06.17	PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers (PR Newswire)
01.06.17	Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome (PR Newswire)
01.06.17	Residential Construction Stocks Under Scanner -- PulteGroup, D.R. Horton, KB Home, and Toll Brothers (PR Newswire)
01.06.17	Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome (PR Newswire)
01.06.17	Sylentis leitet Phase-III-Studie zur Behandlung des Trockenen Auges ein (PR Newswire)
31.05.17	Builder Confidence Trending Upward as New Developments Experience Recent Success (PR Newswire)
31.05.17	Builder Confidence Trending Upward as New Developments Experience Recent Success (PR Newswire)
31.05.17	Partners in Innovation: Whirlpool Corporation Secures 4-Year Renewal with PulteGroup (PR Newswire)
25.05.17	PharmaMar and Eczacıbaşı Sign a Licensing Agreement for Aplidin® in Turkey (PR Newswire)
25.05.17	PharmaMar and Eczacıbaşı Sign a Licensing Agreement for Aplidin® in Turkey (PR Newswire)
19.05.17	PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017 (PR Newswire)
19.05.17	PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017 (PR Newswire)
19.05.17	PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017 (PR Newswire)
18.05.17	PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries (PR Newswire)
18.05.17	PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries (PR Newswire)
09.05.17	PharmaMar: Sylentis Announces New Preclinical and Clinical Data for its SYL1001 Molecule During ARVO 2017 (PR Newswire)
04.05.17	PharmaMar: Aplidin® Receives Orphan Drug Status for the Treatment of Multiple Myeloma in Switzerland (PR Newswire)
27.04.17	PharmaMar Demonstrates Its Progress in R&D in New York (PR Newswire)
26.04.17	Residential Construction Stocks Under Scanner -- PulteGroup, D.R. Horton, KB Home, and Toll Brothers (PR Newswire)
25.04.17	PulteGroup, Inc. Earnings Climb 10% In Q1 (RTTNews)
24.04.17	PharmaMar to Host Research and Development Event today in New York (PR Newswire)
07.04.17	Groundbreaking Of State-Of-The-Art Recreation Center At Reverence Signals Impending Opening Of New Summerlin® Village Built Exclusively By Pulte Homes (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

19.12.24		Zuversicht in New York: S&P 500 mittags mit grünem Vorzeichen
19.12.24		Gute Stimmung in New York: S&P 500 verbucht zum Start Zuschläge
04.12.24		Gewinne in New York: S&P 500 legt mittags zu
04.12.24		Börse New York in Grün: S&P 500 legt zum Handelsstart zu
06.11.24		Optimismus in New York: S&P 500 zum Start im Plus
29.10.24		Börse New York in Grün: S&P 500 beendet die Sitzung im Plus
29.10.24		Börse New York: S&P 500 fester
29.10.24		Optimismus in New York: So bewegt sich der S&P 500 am Mittag

19.12.24

Zuversicht in New York: S&P 500 mittags mit grünem Vorzeichen

19.12.24

Gute Stimmung in New York: S&P 500 verbucht zum Start Zuschläge

04.12.24

Gewinne in New York: S&P 500 legt mittags zu

04.12.24

Börse New York in Grün: S&P 500 legt zum Handelsstart zu

06.11.24

Optimismus in New York: S&P 500 zum Start im Plus

29.10.24

Börse New York in Grün: S&P 500 beendet die Sitzung im Plus